tiprankstipranks
Bluebird Bio Faces Nasdaq Compliance Challenge and Delays
Company Announcements

Bluebird Bio Faces Nasdaq Compliance Challenge and Delays

The latest announcement is out from bluebird bio (BLUE).

Bluebird bio, Inc. has been notified by Nasdaq that due to a delay in filing its annual financial report, it’s out of compliance with Nasdaq’s listing rules. The company has two months to present a plan to regain compliance and potentially six months to submit the report, which has been delayed by the need to restate past financial statements. This notice does not currently affect the company’s Nasdaq listing status, and they aim to submit both the compliance plan and the corrected financial report promptly.

Learn more about BLUE stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskBluebird Bio Welcomes Michael Cloonan to Board of Directors
James FoxBeam Therapeutics Stock (NASDAQ:BEAM): The Future of Gene Editing?
TheFlyJPMorgan biotech analysts hold an analyst/industry conference call
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!